Merck announced on Wednesday a supply and purchase agreement with Singapore that will ensure access to its experimental oral COVID-19 antiviral drug, making Singapore the latest Asian country to seek supplies.
Molnupiravir, the first oral antiviral medication for COVID-19, is designed to introduce errors into the coronavirus’s genetic code. Merck is requesting that the pill be approved by the US Food and Drug Administration.
Singapore’s health ministry confirmed the agreement, but declined to comment on the number of doses purchased due to commercial sensitivities.
According to the ministry, molnupiravir will be available for use after Merck, also known as MSD Pharma in Singapore, submits data to the Health Sciences Authority (HSA) and obtains approval for use in Singapore.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…